investor guide

Shelf Registrations and ATM Programs in Biotech: How to Spot Dilution Before It Happens

Shelf registrations and at-the-money offering programs are how most pre-revenue biotechs raise capital. Here is how to read them in SEC filings and use them as dilution risk signals.

BiotechSign AnalysisOctober 8, 2026

Biotech dilution is not a surprise event. It is a process that unfolds in SEC filings weeks or months before the stock actually falls from a secondary offering. The investors who get hurt are the ones who didn't read the filings. The investors who get out in time, or avoid the position altogether, are the ones who did. Shelf registrations and ATM programs are the two most important filings to understand.

What a Shelf Registration Is

A shelf registration (Form S-3) is a registration with the SEC that allows a company to issue securities, stock, debt, or a combination, on a delayed or continuous basis without filing a new registration statement for each offering. Think of it as a pre-approved credit line with the SEC: once the shelf is declared effective, the company can draw down any amount up to the registered total at any time for up to three years.

The key numbers to extract from an S-3:

  • Total registered amount: The maximum value of securities the company can issue under this shelf. Common amounts for small-cap biotechs: $75M, $150M, $200M, or "up to $X" where X is set relative to current market cap (the SEC's "baby shelf" rule limits smaller companies to issuing no more than one-third of their public float via S-3 in any 12-month period).
  • Previous drawdowns: Has any of this shelf been used? Look for prospectus supplements (424B filings), each one represents a drawdown. The remaining available capacity is the registered total minus all prior drawdowns.
  • Expiration: S-3 shelves are valid for three years from effectiveness. A company approaching the expiration of a large undrawn shelf will often file a new S-3 to refresh it, this is a signal about their ongoing capital planning even if they haven't drawn it.

What an ATM Program Is

An At-The-Market (ATM) equity program is a specific type of shelf drawdown where the company sells shares directly into the open market over time at prevailing market prices. The company registers the shares under the shelf, hires a broker-dealer as agent (commonly Jefferies, Cantor Fitzgerald, or B. Riley), and the broker sells shares into normal trading volume at whatever price the stock is trading.

ATMs are the most dilutive mechanism in small-cap biotech because:

  • They're invisible in real-time. You don't see a sudden secondary offering hit the news. The company is quietly selling shares into every rally.
  • They suppress price recovery. Every time the stock bounces, the company is selling more shares at the higher price, creating a ceiling effect that's hard to break through until the ATM capacity is exhausted.
  • Disclosure is lagged. ATM activity is reported in the quarterly 10-Q or annual 10-K, not in real-time. By the time you see how much was sold last quarter, it's already done.

BiotechSign's dilution risk score tracks shelf registration capacity, ATM use rates, cash runway, and burn rate across all covered biotechs. The score reflects how close a company is to needing to raise capital and how much capacity they have registered to do it quietly.

How to Read an ATM in the Filings

ATMs are established via a prospectus supplement (424B3 or 424B5 filing) that references the underlying shelf registration. The key elements:

  • Maximum aggregate offering amount: How much can be sold under this ATM program total. $50M ATM on a $100M market cap company is very different from a $20M ATM on a $500M company.
  • Agent and commission: The broker-dealer and their fee (typically 2–3%). This is routine; the identity of the agent doesn't signal much.
  • Prior use: Check the most recent 10-K and 10-Q. They will contain a table showing ATM activity for the period, shares sold, average price, gross proceeds, net proceeds. This tells you the pace of dilution.

The pace calculation is the most important piece: if a company's ATM has $40M remaining capacity and they burned through $8M in the last quarter, the remaining capacity represents about five quarters of runway at that pace, and the clock is running.

The Shelf-to-Offering Sequence

Understand the typical sequence for a company approaching a capital raise. This lets you anticipate events before they're announced:

  1. Company files a new S-3 or refreshes an expiring shelf → signals they're planning to raise capital in the next 1–3 years
  2. Company establishes an ATM program via 424B prospectus supplement → they want the quiet dilution option
  3. Company starts reporting ATM sales in quarterlies → active dilution in progress
  4. ATM capacity runs low (or market cap drops too fast for ATM to raise enough) → company announces a bought deal or underwritten secondary offering via S-1 or 424B4 → sharp dilution event with pricing below market

The most dangerous position is entering a stock just before step 4, when the company has run its ATM dry and its cash runway is under 12 months. This is when surprise overnights and dilutive secondaries happen.

The Baby Shelf Rule and Why It Matters for Small Caps

The SEC's "baby shelf rule" (Rule 415) limits companies with a public float below $75 million to issuing no more than one-third of their public float via S-3 in any rolling 12-month period. Companies with floats above $75M are "well-known seasoned issuers" (WKSIs) who can file and use shelves without this cap.

For small-cap biotechs below $75M float, this rule means: once they've raised one-third of their float in the past year, they've exhausted their S-3 capacity and must either wait or file a more expensive S-1 registration. Tracking whether a company has hit its baby shelf limit is a meaningful signal, it tells you they can't do a quiet ATM raise and any capital raise would require an S-1, which takes weeks and is a public event.

What to Check Before Entering Any Small-Cap Biotech Position

  1. Pull the company's EDGAR filings and sort by date. Find their current S-3, is it still effective? How much is registered?
  2. Look for 424B3/424B5 ATM prospectus supplements, has an ATM been established? When?
  3. Check the most recent 10-K and 10-Q for ATM activity tables, how much has been used? At what average price?
  4. Calculate remaining cash runway from the 10-Q cash balance and quarterly burn rate. Under 12 months is a danger zone.
  5. Compare remaining cash runway to remaining ATM capacity. If cash runway is shorter than the ATM can cover, a dilutive secondary is likely.

BiotechSign's dilution risk grade automates this calculation across all covered companies, updating with each new quarterly filing. The grade reflects current shelf capacity, ATM use pace, cash runway, and upcoming cash-consuming catalysts, PDUFA events, clinical milestones, debt maturities, that could accelerate the timeline to the next capital raise.